Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. - Wikidata - awgldk - TriplyDB

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

http://www.wikidata.org/entity/Q46286038

about

The impact of biological interventions for ulcerative colitis on health-related quality of life Anti-MAdCAM antibody for induction of remission in ulcerative colitis Inflammatory bowel disease surgery in the biologic era Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis Advances in the development of new biologics in inflammatory bowel disease The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis Fostering Inflammatory Bowel Disease: Sphingolipid Strategies to Join Forces Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis Optimal management of steroid-dependent ulcerative colitis Promising biological therapies for ulcerative colitis: A review of the literature Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments Pharmacologic therapy for inflammatory bowel disease refractory to steroids Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2 Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis Classical and recent advances in the treatment of inflammatory bowel diseases Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists Review article: anti-adhesion therapies for inflammatory bowel disease Inflammatory pathways of importance for management of inflammatory bowel disease Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis Redeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel disease Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis Next-Generation Therapeutics for IBD Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis Golimumab for the treatment of ulcerative colitis Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.Biologics in inflammatory bowel disease: what are the data?Current approaches to the management of new-onset ulcerative colitis.Golimumab for the treatment of ulcerative colitis.Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease Cost-effectiveness of biological treatment of ulcerative colitis - a systematic review.Adverse events in IBD: to stop or continue immune suppressant and biologic treatment A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases.Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review.

P2860

Q24187078-450A2C22-70A2-406B-908F-9522686EC492 Q24187593-06817017-AB6B-41A9-98BD-7B0B56ACA6EC Q26745627-04F941B2-FD95-40F2-9BF1-7A1309CA97C1 Q26745712-9E6EE393-8C2F-4901-9A60-08289EE24910 Q26745782-7341E974-E5B4-4735-B18D-3F1A08D42BE2 Q26748626-3A289460-1EC0-44C7-B16F-93D388E5596E Q26750190-F824199F-BE8A-4B1E-8DE2-5FD85E5AE6D0 Q26750456-6F9F6347-F89B-43D8-8125-E4D76181C40A Q26764801-B919B4E8-C5CE-4C88-A808-AE227BE4C87A Q26765948-88FE0EB8-80D7-4F67-A78A-160E5E263BBF Q26771136-8408B1DD-E483-4C72-8E01-757ACF245C69 Q26773203-BD095F18-E2C3-45B2-AB9E-3F0E703EAEF6 Q26776139-82BBED72-9C16-4DAF-9172-003BCD3EFB5A Q26785537-CE6AEBAE-FA8D-46E3-A3AF-22A0A542565C Q26796415-C3A7924B-E01B-443C-A170-42715AFC5C9A Q26798299-3FE9213D-5C39-4415-A0AF-A62B845FFA4C Q26823221-9FC02FAA-4929-46D5-8F40-53248CD40C19 Q26861725-1597D875-7616-4B6B-896E-F6E4C2B9C61E Q26862821-CA5F1157-38D6-4443-9F4D-861987942AC4 Q26866940-C00271ED-7005-4DD9-ACC7-11B678432743 Q26999078-D4DAC5F7-9844-413D-AD0E-40414927381D Q26999705-4F963124-8FF7-4BB3-BCF5-7BED3BCB4CE8 Q27005445-80397130-9905-4154-8404-369B7B862C3E Q27006683-89C3E275-A7EC-4D81-AF28-8806DA0DC2B4 Q27027630-F9AACC13-A15B-418F-8B7D-A58B4C23853C Q28067245-AAAE5C56-A2E6-4333-B013-DA4E3F4B86DD Q28079322-8340B465-E29B-44BF-9375-45A8FAA94CFC Q28082306-68ADEA6A-39ED-46E4-AABD-AF925E86403B Q28088683-C3354E45-5CCA-46C4-9EA1-BBF65EB838F9 Q28236322-B83A1014-DCCF-48AA-B8F4-E00B7B6074C7 Q30902172-619B2854-F44A-4A3F-9165-E67DCC194D75 Q31017419-D6FDD410-B00C-4BD6-9AA0-C5928E431BD1 Q33633288-F02B5970-BEA7-466A-A83E-178D7649D5F1 Q33852257-382D4E5E-F924-4D72-8461-A7D6F8843241 Q33865593-E8A45F45-ABA4-4B00-AAA0-7776763D5FD4 Q33871726-8D3D9E6C-8062-4074-9356-655907FF2B8F Q34073191-3E62644D-25B7-4098-99BA-FFA58FBBAC8E Q34353032-11CB16A3-9F54-4F0C-A781-7E8E4E82BC3A Q34487787-E7F66199-5362-4EBB-901E-D7CDEB78529F Q34504710-0B89512E-65CC-4F50-B7D6-6CFE1AF7DBC9

P2860

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

http://www.wikidata.org/entity/Q46286038

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Subcutaneous golimumab induces ...... -to-severe ulcerative colitis.

@en

Subcutaneous golimumab induces ...... -to-severe ulcerative colitis.

@nl

type

label

Subcutaneous golimumab induces ...... -to-severe ulcerative colitis.

@en

Subcutaneous golimumab induces ...... -to-severe ulcerative colitis.

@nl

prefLabel

Subcutaneous golimumab induces ...... -to-severe ulcerative colitis.

@en

Subcutaneous golimumab induces ...... -to-severe ulcerative colitis.

@nl

P1433

Q46286038-28F392F2-2D75-4006-BC3E-C5F4EE74859D

P1476

Q46286038-FBB00ABF-E6D7-4382-B066-66B8897C5B60

P2093

Q46286038-011A214B-5B3B-41C8-A5E8-092CAD68C842

Q46286038-1358C34A-1367-4962-87AC-68D98568CB09

Q46286038-264C47BA-4D3D-4A7D-BC31-47AB9C49DDD2

Q46286038-2CAB1A88-897F-4573-8B73-77298B9EDE79

Q46286038-31ABF3B2-17E1-4766-B6E5-97471D4FEB4C

Q46286038-3988D9A6-5899-4017-9366-6C37593F7BD9

Q46286038-862BBA45-CBD7-4BBB-9708-A688164F5A16

Q46286038-B6497874-5612-4B57-AB19-3222B633EE36

Q46286038-B8E4CD70-0DEE-46F7-ABEF-C4E1C0D610EF

Q46286038-C4287E9C-17B3-467B-8E6D-63B2DC52B333

P304

Q46286038-F963B1B0-137A-40CA-A04F-7EE9B3CA1D84

P31

Q46286038-FDAE915C-B7D4-4A9A-8088-ADD6B83797CD

P356

Q46286038-FD14D8AC-71C8-4E20-B6F4-D197D159DECB

P407

Q46286038-FDE25410-A9B1-4632-BD30-7C3DAAC3A71E

P433

Q46286038-E34E7887-46A6-4A01-9DC8-0CFE48E567DE

P478

Q46286038-E8FC5E20-A78D-413B-A461-4B884AE9FDC4

P50

Q46286038-0918E8B2-D15C-4167-A7CA-30865CC71D39

Q46286038-0C19DD14-91F6-43AD-99D2-631B302D1728

Q46286038-69C2D2CB-1667-494D-B073-49B83E6786B8

Q46286038-F01861A4-8178-4579-923C-FFFC726A69BA

P577

Q46286038-C7EA3941-08C0-4925-9C62-82DBA7B3B612

P698

Q46286038-2A9AB17C-0D96-4323-9C0E-C2C942063AB1

P921

Q46286038-8DA3DE13-472E-4C8E-9629-DE31DBB5E94E

P356

J.GASTRO.2013.05.048

P1433

Gastroenterology

P1476

Subcutaneous golimumab induces ...... -to-severe ulcerative colitis.

@en

P2093

Colleen Marano

http://www.w3.org/2001/XMLSchema#string

Cynthia Guzzo

http://www.w3.org/2001/XMLSchema#string

Gunnar Järnerot

http://www.w3.org/2001/XMLSchema#string

Hongyan Zhang

http://www.w3.org/2001/XMLSchema#string

Jewel Johanns

http://www.w3.org/2001/XMLSchema#string

Judith Collins

http://www.w3.org/2001/XMLSchema#string

Omoniyi J Adedokun

http://www.w3.org/2001/XMLSchema#string

PURSUIT-SC Study Group

http://www.w3.org/2001/XMLSchema#string

Peter R Gibson

http://www.w3.org/2001/XMLSchema#string

Richard Strauss

http://www.w3.org/2001/XMLSchema#string

P304

85-95; quiz e14-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2013.05.048

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

146

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Frédéric Colombel

William Jeffery Sandborn

Brian G. Feagan

P577

2013-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23735746

http://www.w3.org/2001/XMLSchema#string

P921